The Focus On Rhabdo Webinar series is proud to announce our February 2016 webinar speaker was Dr. David Langenau, Director of the Molecular Pathology Unit at the Mass General Hospital in Boston.  His talk centered on the attributes of zebrafish to discover novel therapies and drug pathways that could be exploited in emerging treatments in patients.

 

Dr. David Langenau

Dr. David Langenau is currently an Associate Professor of Pathology at Harvard medical school and the Director of the Molecular Pathology unit at the Massachusetts General Hospital in Boston.

His research focus is to uncover the mechanisms driving progression and relapse in pediatric tumors, including rhabdomyosarcoma. Using novel, transgenic zebrafish models of pediatric sarcoma and leukemia that mimic human malignancy, his group has undertaken studies to discover novel therapies by addition of drugs to the water and imaging tumor growth in live zebrafish.  Moreover, they have utilized detailed imaging studies to visualize tumor cells in live animals and assess how cellular heterogeneity drives continued tumor growth.  Capitalizing on insights gained from zebrafish models of cancer, the Langenau group is now extending findings to human T-cell acute lymphoblastic leukemia and rhabdomyosarcoma.